#Companion Diagnostic Market Report

[new-market-news]

Companion Diagnostic Market Key Players, Dynamics & Latest Trades Report to 2032

Companion Diagnostic Market Report has recently added by Value Market Research, this surveillance report establishing the facts based on current scenarios, historical records from 2023 to future forecast upto 2032. This report explicit data of various outlook such as market share, size, growth rates, and industry opportunities and offering an economical advantage for business success. It furnish the 360-degree overview of the competitive landscape of the global industries. Porter’s Five Forces Model analysis has been used to understand the industry’s structure, strength, weaknesses, opportunities, threats and challenges in front of the businesses.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the companion diagnostics market include Abbott Laboratories Molecular, Inc., Agilent, ARUP Laboratories, Inc., BioMerieux SA, Danaher Corporation. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Get more information on "Global Companion Diagnostics Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/companion-diagnostic-market/download-sample

Market Dynamics

Companion diagnostics are a crucial part of personalized medicine and will likely continue to rapidly increase in the number of disease areas. The next generation of drugs has to be safer and more efficacious. Companion diagnostics are one of the tools that can generate this information and make it available to drug developers. Escalating activities of drug discovery and vaccine development will be driving the market growth. Oncology is a segment of major focus and will remain at the forefront for the foreseeable future. Companion diagnostic play a major role in oncology research and has revolutionized the treatment of cancer by allowing doctors to adjust drug therapy to achieve better clinical results.  However, the high cost and uncertain reimbursement scenario in a different region are hampering the growth of the market.

The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.

Additionally, these tools also give inclusive assessment of each application/product segment in the global market of companion diagnostics.

Browse Global Companion Diagnostics Market Research Report with detailed TOC at https://www.valuemarketresearch.com/report/companion-diagnostic-market

Market Segmentation

The entire companion diagnostics market has been sub-categorized into technology type, and indication. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.

By Technology Type

Immunohistochemistry

Polymerase Chain Reaction

Next Generation Sequencing

In Situ Hybridization

Others

By Indication

Oncology

Neurology

Others

Regional Analysis

This section covers regional segmentation which accentuates on current and future demand for companion diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.

Purchase Complete Global Companion Diagnostics Market Research Report at https://www.valuemarketresearch.com/contact/companion-diagnostic-market/buy-now

About Us:

Value Market Research was established with the vision to ease decision making and empower the strategists by providing them with holistic market information.

We facilitate clients with syndicate research reports and customized research reports on 25+ industries with global as well as regional coverage.

Contact:

Value Market Research

UG-203, Gera Imperium Rise,

Wipro Circle Metro Station, Hinjawadi, Pune – 411057

Maharashtra, INDIA.

Tel: +1-888-294-1147

Email: sales@valuemarketresearch.com

Website: https://www.valuemarketresearch.com

[marketingreportz]

Companion Diagnostics Market - Forecast(2024 - 2030)

 Companion Diagnostic Market Overview:

The Harvard University, while addressing the risk associated with reactions of new drugs prescription, has stated some overwhelming facts. According to their findings, even properly prescribed drugs causes about 1.9 million hospitalizations a year and about 128,000 people die from drugs prescribed to them.[1] Such epidemic condition is being tailgated by the need of safe and effective and specific use of the drug. Owing to such demands, companion diagnostic drug market is poised for exponential growth. Companion diagnostics is an in-vitro diagnostic tool that assists physicians in optimizing treatment decisions for their patients and is crucial for myriad of cancer and other therapies. Riding on the back of economic burden of global healthcare and with abundant potential to restrict the liability, companion diagnostic market size is estimated to be $2,950 million as of 2018.

Inquiry Before Buying

Companion Diagnostic Market Outlook:

Companion diagnostic (CDx) is a diagnostic test used as an associate to a therapeutic drug to regulate its applicability to an individual person. It involves multiple monitoring methods including immunohistochemistry (IHC), polymerase chain Reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), and gene sequencing. The companion diagnostics uses technologies such as molecular biology technique, drug and diagnostic technology, and oncology therapy for the treatment of colorectal cancer, breast cancer, and other chronic diseases.

 An acute analysis of the region-wise companion diagnostic market share concluded with reckoning North America as the most lucrative market for CDx. This region with cutting-edge healthcare technology in the United States and Canada generates 41% of the global companion diagnostic market demand for alarming need for cancer diagnosis and treatment. According to the American Cancer Society, prostate cancer is the most common cancer among males (19%), followed by lung (14%) and colorectal (9%) cancers and among females, breast (30%), lung (12%), and colorectal (8%) cancers are the most common. Increasing instances of cancer along with neurological disorders, infectious diseases, Hepatitis A is augmenting the North American companion diagnostic market.

Companion diagnostic market with abundant potential as an effective tool for personalized medicine has found a tremendous scope of application in pharmaceuticals, laboratories, research institutes and hospitals. Hospital as an end-user industry is the leading segment progressing with an application CAGR of 12.5% going through 2025. Hospitalized patients account for a total of 2.74 million serious adverse drug reactions. Each CDx test is specifically designed to be corresponding with an exact drug. Such tests can also save significant hospital expenditure by targeting specific patients with the most effective therapy.

Request Sample

 Companion Diagnostic Market Trends and Growth Drivers:

·         The necessity for personalized therapeutics for the cumulative geriatrics population and the increasing figure of diagnostics centers in both the developed and developing economies is predominant to determine profits in the global companion diagnostics market.

·         FDA had issued "Guidance for Industry: In Vitro Companion Diagnostic Devices," to assist syndicates recognize the necessity for companion diagnostics at an initial stage in the drug development procedure and to strategize for co-development of the drug and companion diagnostic test.

 On July 15, 2016, FDA introduced the draft regulation, "Principles for Co-development of an In Vitro Companion Diagnostic Device with a Therapeutic Product." This guidance text is envisioned to be a practical guide to support therapeutic product promoters and IVD sponsors in evolving a therapeutic product and an associated IVD companion diagnostic. The scientific progressions in the in-situ hybridization and automated silver-enhanced in-situ hybridization (SISH) for the monitoring of genes is trending in the global companion diagnostics market.

Schedule a Call

 Companion Diagnostic Market Players Perspective:

Some of the key players influencing the global market are:-  Abbott Laboratories, Agilent Technologies, biomerieux, Bio-Genex Laboratories, Danaher Corporation, GE Healthcare, Myriad Genetics, Inc., QIAGEN N.V., R-Biopharm AG, and Roche Diagnostics.

In April 2017, Abbott acquired Alere for a new price of about $5.3 billion. Alere is the global leader in point of care diagnostics focused on the areas of infectious disease, molecular, cardiometabolic and toxicology. The collective business will offer the biggest point of care menu of infectious disease, molecular, cardiometabolic and toxicology testing. Abbott's platforms will be expanded to comprise benchtop and rapid strip tests.

Buy Now

 Companion Diagnostic Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the companion diagnostic market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the various diagnostics in companion diagnostic market, and their specific advantages.

[tritonmarketresearchamey]

Companion Diagnostics Market: What’s New?

With rising health consciousness and expenditure, precision medicine has emerged as a major solution to treating chronic conditions. Estimates indicate that the personalized medicine segment is expected to account for around 40% by the end of 2022, with oncology being a major therapeutic area. As a result, this growth is expected to support the expansion of the companion diagnostics market as CDx tests identify the right drug for a specific patient pool.

Triton Market Research’s report infers that the global companion diagnostics market is expected to progress at a CAGR of 12.84% during the forecast period 2022-2028.

Presently, medical treatments are typically designed using uniform patterns, with patients with the same disease undergoing matching treatments. This trial-and-error style often becomes time-consuming and ineffective. Hence, the development of precision medicine with the help of CDx widens the studied market’s scope.

CDx Development: Technological Advancements Backs Regional Growth

In addition to a growing focus on precision medicine, the expansion of the companion diagnostics market is also fueled by technological advancements. Top trends that support the market’s growth globally, especially in the Asia-Pacific, include:

Predictive Biomarkers have proven vital in calculating responses to certain therapeutic interventions. For instance, the Oncotype Dx and MammaPrint tests and KRAS employ predictive biomarkers, providing the most effective treatment to breast and colorectal cancer patients. Estimates suggest that the oncology category secures the majority of shares in the market in terms of indication. As a result, biomarkers have gained significant prominence among oncologists across nations, including India. For instance, Tata Memorial Hospital, NIMHANS, and AIIMS are striving to identify new genes and biomarkers, ultimately generating opportunities for the Asia-Pacific companion diagnostics market.

Polymerase Chain Reaction (PCR) leads the mechanism segment in terms of revenue share in 2022. It is projected to evolve at a CAGR of 13.13% during the forecasted period. Factors such as cost-efficient, faster turnaround time, and ease of application have supported its dominance in neurology and oncology applications. Besides this, PCR-based CDx has witnessed substantial growth due to approvals such as BRACAnalysis CDx by Myriad Genetics. Such developments are expected to influence market players to expand their PCR capabilities, augmenting the companion diagnostics market’s development.

Next Generation Sequencing is another major technology fueling the CDx market development. Since NGS permits rapid sequencing, it has supported major advances in determining the molecular basis of various chronic conditions. NGS is expected to become the fastest-growing segment in the mechanism category. In this regard, PCR techniques are expected to support the success of NGS technology in the upcoming years. To illustrate, NGS diagnosis and PCR techniques offer high-precision care with less turnaround time. The rising competency in genome sequencing has also generated substantial opportunities for vendors like Shuwen Biotech and Simcere Diagnostics in the Chinese companion diagnostics market.

Competitive Landscape: Strategic Highlights & Latest CDx Approvals

The inclusion of analytics and big data has helped identify various biomarker-based illness indications regularly. This has triggered businesses to enter the market through innovations. Moreover, since it’s easy to shift from one product to another, the competition among existing players has elevated over the years. Such developments have thus led to the advent of new strategies to launch and gain approvals for their CDx devices.

In August 2022, Roche Diagnostics gained approval from FDA for VENTANA MMR RxDx Panel, the first immunohistochemistry CDx test. Based on cancer biomarkers, it helps detect solid tumor patients.

Foundation Medicine’s FoundationOne CDx and Liquid CDx were authorized with various companion diagnostics claims by the FDA in June 2022.

In May 2022, BioMerieux announced approval from FDA for its BIOFIRE Joint Infection Panel. The panel tests for 31 pathogens implicated in acute joint infections and contains 8 AMR genes to optimize therapy.

Evotec SE and BioMeriux, in July 2022, declared their partnership to create the next generation of antimicrobial and actionable diagnostics to prevent antimicrobial resistance.

In July 2021, Illumina expanded its oncology partnerships with Bristol Myer Squibb, Kura Oncology, Myriad Genetics, and Merck. This joint venture aims to develop tools for precision oncology.

Growth Prospects: CDx for Targeted Cancer Medication

Earlier, the commercial success of Herceptin and Gleevec revolutionized companion diagnostics globally. However, the increased prevalence of cancer cases has led to a dramatic shift in the drug development process, from uniform to precision medicine approach, increasing the need for new CDx solutions. Hence, the demand for predictive biomarkers for targeted cancer therapeutics is expected to take center stage, thereby creating opportunities for the companion diagnostics market.

FAQ:

Q1) What is the size of the companion diagnostics market?

The companion diagnostics market obtained $5314.48 million and is expected to gain revenue worth $12740.68 million by 2028.

Q2) What are the key end-users of the companion diagnostics market?

The key end-users include pharmaceutical and biopharmaceutical companies, reference laboratories, and others.

[mitalipingale]

https://justpaste.it/20xzf

The Companion Diagnostics Market in 2023 is US$ 6.83 billion, and is expected to reach US$ 16.22 billion by 2031 at a CAGR of 11.40%.

[animal-care]

Expanding Opportunities in the Animal Health Market: Trends and Outlook

Introduction

The Animal Health Market is witnessing dynamic growth and evolution, fueled by changing consumer preferences, advancements in veterinary medicine, and increasing awareness of animal welfare. In this blog, we explore key trends shaping the animal health industry and provide insights into the market's outlook for the future.

Rise of Pet Ownership

One of the most notable trends driving the animal health market is the growing popularity of pet ownership. As more people welcome pets into their homes, demand for veterinary services, pet care products, and preventive healthcare measures is on the rise. This trend is particularly evident in urban areas, where pet ownership is becoming increasingly common among young professionals and families.

Focus on Preventive Care

Preventive healthcare has emerged as a key priority for pet owners, leading to increased demand for vaccines, parasite control products, and wellness exams. Veterinarians are increasingly emphasizing the importance of regular check-ups and preventive treatments to maintain pets' health and detect potential issues early. This shift towards proactive healthcare is driving growth in the animal health market.

E-Commerce Boom

The rise of e-commerce platforms has transformed the way pet owners access veterinary products and services. Online retailers offer a wide range of pet care products, prescription medications, and veterinary supplies, providing convenience and accessibility to pet owners. This trend is expected to continue, with e-commerce projected to play an increasingly important role in the distribution of animal health products.

Focus on Animal Welfare

Consumer awareness of animal welfare issues is driving demand for ethically sourced and sustainably produced animal products. This includes pet food, livestock feed, and pharmaceuticals used in animal health care. Companies in the animal health market are responding to these demands by implementing sustainable practices, ensuring the welfare of animals throughout the supply chain.

Technological Advancements

Advancements in technology are revolutionizing the practice of veterinary medicine, with innovations such as telemedicine, digital health monitoring, and artificial intelligence gaining traction. These technologies enable veterinarians to deliver remote care, monitor patients' health in real-time, and make data-driven treatment decisions. As technology continues to advance, it is expected to further enhance the quality and accessibility of veterinary care.

Regulatory Landscape

The Animal Health Market is subject to a complex regulatory landscape, with stringent requirements for product safety, efficacy, and labeling. Regulatory agencies play a critical role in ensuring the quality and integrity of veterinary products and services, safeguarding animal and human health. Companies operating in the animal health market must navigate these regulatory requirements to bring products to market and maintain compliance.

Global Expansion Opportunities

The animal health market offers significant opportunities for global expansion, particularly in emerging markets with growing pet populations and increasing disposable income. Asia-Pacific, Latin America, and the Middle East are emerging as key growth regions for the animal health industry, presenting opportunities for investment and market expansion.

Conclusion

The animal health market is experiencing rapid growth and transformation, driven by evolving consumer preferences, technological advancements, and regulatory developments. From the rise of pet ownership and the focus on preventive care to the adoption of e-commerce and the expansion into global markets, the animal health industry is poised for continued growth and innovation. By staying abreast of key trends and embracing opportunities for innovation and expansion, stakeholders in the animal health market can position themselves for success in this dynamic and evolving industry.

[crop-protection-market]

Exploring the Animal Care Market: A Global View of Share, Growth, and Future Outlook

The Animal Care Market, a domain driven by compassion and dedication, plays a vital role in safeguarding the well-being of our cherished animal companions. This comprehensive overview dives into the intricacies of the Animal Care Market, encompassing analysis, demand dynamics, growth projections, challenges, and emerging trends.

Compassionate Care: Unveiling the Landscape of the Animal Care Market

Beyond being an industry, the Animal Care Market is a testament to our commitment to providing optimal care for our diverse animal companions. Analyzing its multifaceted nature reveals the delicate balance between technological advancements, regulatory compliance, and the unwavering dedication of caregivers. The Global Animal Care Market Size is poised to reach USD 100 billion by 2025, reflecting a compounded annual growth rate of 6%. Notably, the Asia-Pacific region leads the way, holding a substantial 35% share of the total market revenue.

Meeting the Demand: Addressing the Needs of Pets and Livestock

Understanding the demand dynamics within the Animal Care Market is pivotal for stakeholders aiming to cater to the diverse needs of both pet owners and livestock producers. The surge in pet adoption, evolving pet humanization trends, and a growing awareness of preventive veterinary care collectively drive Animal Care Market Demand. Additionally, rising concerns about zoonotic diseases and the push for sustainable livestock practices significantly contribute to the demand for animal health products. Remarkably, pet owners in North America annually invest an average of USD 1,200 in veterinary care and related products.

Forecasting a Brighter Future: Growth and Outlook of the Animal Care Market

Navigating the trajectory of growth and forecasting future trends is essential for stakeholders contributing to the positive development of the Animal Care Market. The Animal Care Market Outlook is optimistic, fueled by sustained demand for advanced veterinary services, pet insurance, and innovative healthcare products. Government initiatives promoting animal health and welfare further contribute to this positive growth outlook. The Latin American region is anticipated to experience the highest growth rate in the Animal Care Market, with a projected CAGR of 8% over the next five years.

Revenue Realities: Illuminating the Financial Landscape of Animal Care

Delving into the revenue aspects of the Animal Care Market unveils the economic viability of the industry and the financial considerations influencing stakeholders. The Animal Care Market Revenue is diverse, spanning veterinary services, pet products, and pharmaceuticals. The uptick in pet ownership, coupled with an increased willingness to invest in premium pet products and services, significantly contributes to market revenue. Veterinary services specifically contribute to 50% of the total Animal Care Market Revenue, showcasing the growing emphasis on professional healthcare for pets.

Sizing Up: Animal Care Market Size and Emerging Trends

Analyzing the size of the Animal Care Market alongside emerging trends provides a comprehensive view of the industry's current state and future possibilities. The Animal Care Market Size is witnessing a surge in demand for organic and natural pet care products. Notably, e-commerce platforms are gaining popularity for purchasing pet products, reflecting shifts in consumer buying behavior. Online sales of pet care products have witnessed a substantial 25% year-on-year increase, signaling the digital transformation of the Animal Care Market.

Challenges on the Horizon: Navigating Animal Care Market Challenges

While the Animal Care Market thrives on compassion, it is not immune to challenges that demand thoughtful solutions. Animal Care Market Challenges include regulatory complexities, the increasing need for skilled veterinarians, and ethical considerations surrounding animal testing. The rise in counterfeit animal health products poses a significant challenge to the integrity of the Animal Care Market. The shortage of skilled veterinarians, estimated at 20% in developing regions, impacts the accessibility of veterinary services.

The Ever-Changing Landscape of Animal Care Market Trends

Remaining at the forefront of the Animal Care Market involves a keen awareness of emerging trends shaping the industry's future. Animal Care Market Trends include the rising demand for personalized pet nutrition, the integration of telehealth services in veterinary care, and the growing popularity of pet wearables. Sustainable and eco-friendly practices are gaining prominence, with consumers seeking ethically sourced and environmentally conscious animal care products. The market for pet wearables is expected to witness a remarkable CAGR of 12% over the next five years, driven by the increasing focus on pet health monitoring.

Conclusion: A Commitment to Compassion and Innovation

The Animal Care Market stands as a testament to our unwavering commitment to the well-being of our animal companions. Navigating its complexities requires a blend of compassion, innovation, and a proactive response to emerging trends and challenges. As the market continues to evolve, stakeholders must remain adaptable and dedicated to ensuring the health and happiness of the creatures we cherish.

[mrudula01]

Global Companion Diagnostics Market is Anticipated to Progress at a CAGR of 12.84% by 2028

Triton Market Research presents the Global Companion Diagnostics Market report segmented by Consumer (Reference Laboratories, Pharmaceutical and Biopharmaceutical Companies, Other Consumers), Mechanism (Polymerase Chain Reaction, Next Generation Sequencing, In-Situ Hybridization, Immunohistochemistry, Other Mechanisms), Indicator (Neurology, Oncology, Infectious Disease, Other Indicators), Commodity (Software & Services, Assay Kits & Reagents), and Regional Outlook (Europe, Asia-Pacific, North America, Latin America, Middle East and Africa).

The report further discusses the Market Summary, Industry Outlook, Impact of COVID-19, Key Insights, Porter’s Five Forces Analysis, Market Attractiveness Index, Vendor Scorecard, Drivers, Challenges, Opportunities, Competitive Landscape, Research Methodology & Scope, Global Market Size, Forecasts & Analysis (2022-2028).

As per Triton’s research report, the global companion diagnostics market is estimated to witness growth at a CAGR of 12.84% during the forecast period 2022-2028.

A companion diagnostics device helps attain crucial data to efficiently match a drug or therapy. It is a personalized treatment that includes drug testing, clinical trials, and research.

Genome sequencing has emerged as a significant step in the gene therapy process. This has increased investments in next generation gene sequencing. Moreover, the rising research in the space is expected to promote the companion diagnostics market’s growth. Furthermore, the growing investments and research in precision medicine are also anticipated to elevate the demand for companion diagnostics tests, thereby opening new avenues for the studied market.

However, a weak reimbursement framework and common cases of leakage in oncology companion diagnostics restrict the companion diagnostics market’s growth.

Globally, the Asia-Pacific is expected to emerge as the fastest-growing region over the forecast period. The region is witnessing growth owing to the increasing development of precision medicine technology. Moreover, an initiative undertaken by regulatory authorities and the pharmaceutical industry to increase precision medicine development drives the demand for companion diagnostics tests. Above all, the increase in healthcare awareness and economic growth are expected to open new avenues for the companion diagnostics market.

Danaher Corporation, GE Healthcare, Roche Diagnostics, Arup Laboratories, Almac Group, Thermo Fisher Scientific, Genomic Health, Myriad Genetics, Illumina Inc, bioMerieux, Qiagen, Biocartis, Sysmex Corporation, Agilent, and Abbott Laboratories are leading companies in the companion diagnostics market.

Companies in the market offer relatively similar products with small variations in terms of efficiency and capabilities. As a result, establishments are seeking to develop products with new features. The new entrants are required to invest a significant amount in order to adopt new technology and establish workstations. On the other hand, companies active in the market allocate significant resources, covering the majority of initial expenditures. Hence, these factors indicate the threat of new entrants to be medium.

[markettrend24]

Companion Animal Diagnostic Market risks and challenges that the industry is facing

Companion Animal Diagnostic Market risks and challenges that the industry is facing

The Companion Animal Diagnostic Market research report 2022-2030 provides an in-depth analysis of the changing trends, opportunities, and challenges influencing the growth over the next decade. The study includes a detailed summary of each market along with data related to demand, supply and distribution. The report examines Companion Animal Diagnostic market growth strategies adopted by leading…

[bisresearchreports]

Companion diagnostics refers to the process of developing the targeted medicine along with the biomarker-based testing. Companion diagnostics also aid in locating patient-related data and make it easier to utilise focused therapies.

[technicaldr]

How Patient Care Is Being Improved by Technology Everyday

With technology becoming more integral to patient care in recent years, innovation in the medtech space is progressing at an unprecedented level. From streamlining long-held manual processes to creating entirely new diagnostic devices, new tech is cropping up all over the industry—resulting in a real-world impact on patients’ quality of life.

  These technologies are helping companies to enable faster and more efficient engagement with patients, improve traditional devices, incorporate more software solutions into patient care, and even launch wholly new products. Further, these modern tools help medtech companies keep up with the rapid pace of innovation, by launching new products faster and quickly extending to new markets.

As hospitals face consolidation and CIOs are asked to increase staff productivity, tech companies that can support automation with solutions that are easy to onboard are getting heightened interest.

  Streamlining quality processes for the better

  In medtech especially, quality is the name of the game. The speed at which companies can address post-market or field issues is vital to success. After all, if a product meant to improve patient care isn’t performing the way it’s intended to, there could be tangible life-saving implications.

The secret to speedy post-market action is automating and integrating what was once a manual and disparate case-to-complaint and reportability process, by using a single enterprise platform.

For instance, imagine a company that wants to decrease their issue-to-resolution times. Their cases can be automatically tied to complaints and propagate common data, enabling faster investigations, reportability determination and electronic submissions.

  The Covid-19 pandemic has forced life sciences companies to take a fresh look at how they do business. But as they reinvent their operations, companies often overlook a critical function: Their learning and development programs.

  Also, their enterprise technology enables them to capture nonconformances with batch details which can quickly trigger ship holds, dispositions, and field actions.

And many of these major innovations trickle downstream to corrective and preventive actions (CAPA), Engineering Change Orders (ECOs), and business processes.

Having the ability to close the quality loop throughout the entire enterprise value chain can not only revolutionize a necessary process, it can deliver better patient experiences and outcomes.

  Improving traditional therapies 

  While headlines about new strains of Covid-19 and Monkeypox continue to circulate, the most common chronic diseases continue to grow at alarming rates.

Technology is helping to both manage difficult symptoms of these diseases, and find proactive ways to prevent them before the onset.

Advances in technology are giving patients their independence back. Think of how much easier a diabetes patient’s day-to-day life would be by conducting therapies in their own home instead of adjusting their scheduling around trips to the hospital for recurring appointments. Not to mention the lowered cost.

Imagine a world where therapies for type 2 diabetes (T2D) have the potential to prevent or even reverse its course. In the U.S. alone approximately 30 million people are diagnosed with T2D and half of them have difficulty controlling it.

  Leveraging software as a medical device (SaMD)

  Smart technology is virtually inescapable today. We use software devices in many aspects of our lives—in our homes, in our cars, in our pockets. And our medical needs are no exception.

Software as a Medical Device (SaMD) is one of the fastest growing areas of medtech innovation, enabling tangible life-saving results from:

Remote patient monitoring Faster, more accurate disease diagnosis and treatment decisions, such as stroke and pulmonary issues

Streamlined workflows & coordination for care teams

Digital Therapeutics and Digital Companions

…and the list is increasing exponentially. SaMD has changed how patients manage their health and interact with healthcare professionals.

  Ushering in the future of care

  The pace of medtech innovation is accelerating so much it almost feels as if we’ve stepped into the future. There are groundbreaking companies focused on eradicating certain cancers that are offering comprehensive genomic profiling (CGP) which provides results from a simple blood draw in days. This allows oncologists to obtain information quicker and advise the right treatment to each of their cancer patients.

This is just one example of how patients at all stages of cancer can live longer and healthier through the power of blood tests and the data they unlock.

  The secret weapon 

  The secret weapon is the ability to connect all business processes on a single platform solution. Keeping pace with top innovators requires a modern system to manage integrated change processes and cross-functional collaboration across the entire product and software lifecycle.

The critical and complex products that patients rely upon demand responsibility to ensure the best availability, quality, outcomes and uptime.

Technical Doctor's insight:

Contact Details : inquiry@technicaldr.com or 877-910-0004 www.technicaldr.com

[tamanna31]

Pharmacovigilance Market Size, Share, Growth, Analysis Forecast to 2030

Pharmacovigilance Industry Overview

The global pharmacovigilance market size was estimated at USD 7.32 billion in 2023 and is anticipated to grow at a CAGR of 6.8% from 2024 to 2030.

The rising incidence of Adverse Drug Reactions (ADRs) owing to drug abuse and the prevalence of diseases that require a combination of drugs are the major growth drivers for the market. In addition, an upward shift in the production of novel drugs and the presence of stringent government regulatory frameworks for drug safety are significantly boosting the market growth. For instance, the U.S. FDA and the EU’s European Medical Agency (EMA) formulate regulatory guidelines for all phases of clinical trials. Moreover, advancements in the development of ADR databases and information systems have enabled accurate reporting of information, which can be further utilized by research professionals for prospective clinical studies, thereby fueling overall growth.

Gather more insights about the market drivers, restrains and growth of the Pharmacovigilance Market

A rise in the incidence of chronic diseases, such as cancers, diabetes, and cardiovascular & respiratory disorders, has led to an increase in drug consumption worldwide. According to a WHO report on pharmaceutical consumption, medicines to treat chronic diseases accounted for a larger proportion of the total volume of drug consumption in nonhospital setups. Increasing drug development activities in areas such as personalized medicines, biosimilars, orphan drugs, and companion diagnostics, along with adaptive trial designs, is projected to boost the demand for pharmacovigilance services in the coming years.

Furthermore, the increasing incidence of ADR and drug toxicity is fueling the market growth. According to the National Center for Biotechnology Information (NCBI), approximately 5% of total hospitalizations in a year are due to ADR in Europe. Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious Adverse Drug Reactions (ADRs) in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade.

Browse through Grand View Research's Healthcare IT Industry Research Reports.

The global personalized medicine market was valued at USD 529.28 billion in 2023 and is projected to grow at a CAGR of 8.20% from 2024 to 2030.

The global medical writing market size was valued at USD 3.8 billion in 2022 and is expected to expand at a CAGR of 10.46% from 2023 to 2030.

Key Pharmacovigilance Company Insights

The market is characterized by a few notable players, including Accenture, IQVIA, Cognizant, Aris Global, and IBM Corporation. These manufacturers are actively utilizing strategic initiatives such as mergers and acquisitions to strengthen their market positions. For instance, in October 2023,  IQVIA strategically collaborated with argenx to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and solutions.

"We look forward to collaborating closely with IQVIA on this important business need. We aim to innovate in all that we do and IQVIA’s technology-enabled PV services and solutions will allow for efficient data integration as we work to bring new treatment options to autoimmune patients”.

- Tim Van Hauwermeiren, CEO, argenx.

In November 2022, Linical Americas (a U.S. subsidiary of The Linical Group) and Science 37 Holdings, Inc. announced a partnership to enable the deployment of hybrid and fully decentralized trials. This partnership will provide enhanced access to Linical’s offerings.

“By partnering with Linical, we have an important new ally in our mission to accelerate clinical research and enable universal access for patients,” “Our technology-enabled Metasite will empower and enhance Linical’s solutions, helping patient’s access new life-changing treatments quicker, in the largest and most prevalent therapeutic areas.”

- ”David Coman, Chief Executive Officer of Science 37

Recent Developments

In March 2023, ICON plc and LEO Pharma announced partnerships to impel execution of clinical trials in medical dermatology space.

“We’ve been exploring several outsourcing models but found a hybrid sourcing model to be the most efficient. Partnering with ICON supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business through scalability and flexibility. “ICON’s wealth of services and leading position in clinical development will support LEO Pharma’s R&D strategy building on driving innovation through partnerships and support staying competitive.”

- Jörg Möller, Executive Vice President and head of Global R&D at LEO Pharma

In February 2023, Parexel International Corporation announced the launch of Expert Series-New Medicines, Novel Insights. The series features latest insights from company’s cross-functional experts postanalysis of trends that impact drug development and evidence-based guidance for the biopharmaceutical industry.

“Cutting-edge medicines are becoming more personalized and precise across the therapeutic landscape, while the process to develop those therapies is reaching new heights of complexity. “Parexel’s New Medicines, Novel Insights research series offers expert-led guidance to deliver on the promise of patient-focused drug development and bring impactful treatments to patients more rapidly.”

- Amy McKee, MD, Chief Medical Officer and Head of Oncology Center of Excellence

Key Pharmacovigilance Companies

The following are the leading companies in the pharmacovigilance market These companies collectively hold the largest market share and dictate industry trends

Accenture

IQVIA Inc.

Cognizant

Clinquest Group B.V. (Linical Americas)

IBM

Laboratory Corporation of America Holdings

ArisGlobal

Capgemini

ITClinical

ICON plc.

TAKE Solutions Limited

Parexel International (MA) Corporation

Wipro

United BioSource LLC

BioClinica Inc. (Clario)

ClinChoice (formerly FMD K&L

Order a free sample PDF of the Pharmacovigilance Market Intelligence Study, published by Grand View Research.

[kathansky]

Companion Diagnostics Market Global Latest Trends and Insights 2024 to 2031

Leading market research firm SkyQuest Technology Group recently released a study titled 'Companion Diagnostics Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Companion Diagnostics report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Companion Diagnostics Market extensively demonstrates existing and upcoming opportunities, profitability, revenue growth rates, pricing, and scenarios for recent industry analysis.

The research analysis on the global Companion Diagnostics Market report 2024 offers a close watch on top industry rivals along with briefings on their company profiles, strategical surveys, micro as well as macro industry trends, futuristic scenarios, analysis of pricing structure, and an all-encompassing overview of the Companion Diagnostics Market circumstances in the forecast period between 2024 and 2031. The global Companion Diagnostics Market is a dynamic and rapidly evolving sector, encompassing the development, production, and distribution. This market is essential for improving global market and driving economic growth through innovation and industry advancements. Market Growth The Companion Diagnostics Market has experienced robust growth over the past decade and is projected to continue expanding. The Global Companion Diagnostics Market is poised to grow from USD 7.37 Bn in 2023 to USD 17.48 Bn by 2031, at a CAGR of 11.4% over the forecast period 2024–2031 This growth is driven by several factors, including an aging global population, increasing prevalence of advancements in technology, and rising global expenditure.

Chance to get a free sample @ https://www.skyquestt.com/sample-request/companion-diagnostics-market 

Detailed Segmentation and Classification of the report (Market Size and Forecast - 2031, Y-o-Y growth rate, and CAGR): The Companion Diagnostics Market can be segmented based on several factors, including product type, application, end-user, and distribution channel. Understanding these segments is crucial for companies looking to target specific markets and tailor their offerings to meet consumer needs.

Product and Services

Assays, Kits, Reagents, and Software & Services

Technology

PCR and ISH

Indication

Cardiovascular and oncology 

Get your customized report @ https://www.skyquestt.com/speak-with-analyst/companion-diagnostics-market 

Following are the players analyzed in the report:

Abbott 

IDVet 

F. Hoffmann-La Roche Ltd.  

Agilent Technologies, Inc.  

AniCell Biotech 

Illumina, Inc.  

Guardant Health 

Heska Corporation 

Thermo Fisher Scientific Inc.  

BIOMERIEUX  

NEOGEN Corporation 

Zoetis Inc. 

QIAGEN  

Myriad Genetics, Inc. 

Virbac SA 

Regional Analysis 1. North America: - The United States and Canada dominate the North American Companion Diagnostics Market. The U.S. is the largest market globally, driven by advanced global infrastructure, high R&D investments, and significant Companion Diagnostics consumption. 2. Europe: - Europe is a significant player, with major Companion Diagnostics Markets in Germany, France, and the United Kingdom. The region benefits from strong regulatory frameworks, high industry standards, and a robust R&D sector. 3. Asia-Pacific: - This region is experiencing rapid growth, with countries like China and India leading the charge. Factors such as increasing industry access, growing middle-class populations, and expanding Companion Diagnostics manufacturing capabilities contribute to this growth. 4. Latin America: - Brazil and Mexico are key markets in Latin America. Growth in this region is driven by rising industry needs, increasing investments in industry infrastructure, and a growing demand for affordable medications. 5. Middle East and Africa: - The Companion Diagnostics Market in this region is expanding due to rising market spending, increased prevalence of diseases, and improvements in Market infrastructure, although the market is relatively smaller compared to other regions. Future Outlook The Companion Diagnostics Market is poised for continued growth driven by technological advancements, expanding global market access, and increasing global industry needs. As the industry adapts to evolving challenges and seizes emerging opportunities, it is likely to see ongoing innovation and expansion, contributing significantly to global health and economic development.

Buy your full report: https://www.skyquestt.com/buy-now/companion-diagnostics-market 

[amrutatbrc1]

Clinical Oncology Next Generation Sequencing Market 2024 : Size, Growth Rate, Business Module, Product Scope, Regional Analysis And Expansions 2033

The clinical oncology next generation sequencing global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Clinical Oncology Next Generation Sequencing Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.45 billion in 2023 to $0.52 billion in 2024 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to genomic research advances, cancer biomarker discovery, technological advancements, regulatory approvals.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to growing cancer incidence, precision medicine, immuno-oncology, liquid biopsies. Major trends in the forecast period include comprehensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, ai and machine learning.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Market Drivers - The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next-generation sequencing market during the forecast period. According to the American Cancer Society, there were 1.9 million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the growth of the clinical oncology next-generation sequencing market.

The clinical oncology next generation sequencing market covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing 2) By Application: Screening, Companion Diagnostics, Other Diagnostics 3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories

Get an inside scoop of the clinical oncology next generation sequencing market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Regional Insights - North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Key Companies - Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

Table of Contents 1. Executive Summary 2. Clinical Oncology Next Generation Sequencing Market Report Structure 3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies 4. Clinical Oncology Next Generation Sequencing Market – Macro Economic Scenario 5. Clinical Oncology Next Generation Sequencing Market Size And Growth ….. 27. Clinical Oncology Next Generation Sequencing Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[prajwal-agale001]

Latin America Molecular Diagnostics Market Overview: Challenges and Growth Opportunities

According to a recent report by Meticulous Research®, the Latin America molecular diagnostics market is forecasted to reach $2.50 billion by 2031, expanding at a compound annual growth rate (CAGR) of 6.3% from 2024 to 2031. The market growth is propelled by several key factors, including the increasing global geriatric population, rising prevalence of communicable and noncommunicable diseases, rapid advancements in molecular diagnostics technology, and a surge in healthcare spending across the region.

The rising demand for molecular diagnostics in Latin America is further supported by opportunities such as the expanding scope in emerging economies, increased focus on companion diagnostics, and the growing popularity of direct-to-consumer (DTC) testing. Despite these growth drivers, challenges like the shortage of skilled professionals, unfavorable regulatory frameworks, and the high costs of molecular diagnostic tests could restrain the market’s growth.

Download Sample of Report @ https://www.meticulousresearch.com/download-sample-report/cp_id=5759

Market Segmentation and Key Insights

The Latin America molecular diagnostics market is segmented based on offerings, test types, technologies, applications, and end users.

By Offering: In 2024, the kits and reagents segment is expected to dominate the market. This is attributed to the widespread availability of diagnostic reagents and consumables, disease-specific test kits and assays, and increasing awareness about the importance of early disease diagnosis.

By Test Type: The laboratory tests segment is projected to account for the largest share in 2024. Laboratory tests remain the preferred choice for hospitals, diagnostic laboratories, and academic institutions, driven by their wide availability and the significant developments in diagnostic testing within clinical settings.

By Technology: The polymerase chain reaction (PCR) segment is expected to lead the market in 2024. PCR's dominant position is due to its versatility in multi-drug resistance testing, widespread use in clinical and research laboratories, and applications in areas such as DNA fingerprinting, bacterial and viral detection (particularly HIV/AIDS), and genetic disorder diagnosis.

By Application: The infectious diseases segment is anticipated to hold the largest share of the market in 2024. The increasing prevalence of infectious diseases, rising funding for the development of innovative diagnostic tools, and the heightened focus on diagnostic technologies during the COVID-19 pandemic are driving the demand for molecular diagnostics in infectious disease management.

By End User: Hospitals and clinics are expected to dominate the market by end user in 2024. The growing number of hospitalizations due to a variety of diseases requiring molecular diagnosis, coupled with the proliferation of healthcare facilities in countries such as Brazil, Mexico, Chile, and Colombia, is contributing to the expansion of molecular diagnostic product utilization in this segment.

Key Industry Players

The competitive landscape of the Latin America molecular diagnostics market is shaped by several prominent global and regional players. Leading companies in the market include:

Bio-Manguinhos (Brazil)

F. Hoffmann-La Roche Ltd. (Switzerland)

Thermo Fisher Scientific Inc. (U.S.)

Hologic, Inc. (U.S.)

Illumina, Inc. (U.S.)

OmicronLab (Mexico)

QIAGEN N.V. (Netherlands)

Danaher Corporation (U.S.)

Abbott Laboratories (U.S.)

Agilent Technologies, Inc. (U.S.)

These companies are at the forefront of innovation and technological advancements in molecular diagnostics, driving market growth through product development, partnerships, and strategic expansions.

Opportunities and Challenges

The Latin America molecular diagnostics market is ripe with opportunities, particularly in emerging economies where there is increasing demand for advanced diagnostic tools. The rising focus on companion diagnostics and the expanding DTC testing market offer significant growth prospects. However, challenges such as the high cost of molecular diagnostic tests and regulatory hurdles may hinder market expansion.

Despite these challenges, the region’s healthcare landscape is undergoing rapid transformation, with increasing healthcare investments and advancements in diagnostic technologies expected to fuel further growth.

Read Full Report @ https://www.meticulousresearch.com/product/latin-america-molecular-diagnostics-market-5759

Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

[mitalipingale]

https://www.shtfsocial.com/blogs/142854/Companion-Diagnostics-Market-Analysis-Size-Share-and-Forecast-2031

The Companion Diagnostics Market in 2023 is US$ 6.83 billion, and is expected to reach US$ 16.22 billion by 2031 at a CAGR of 11.40%.

[animal-care]

Exploring Trends Shaping the Animal Care Market

The Animal Care Market is undergoing significant transformations driven by evolving consumer preferences, technological advancements, and emerging trends. In this article, we delve into the latest trends shaping the landscape of the animal care industry and their implications for market players.

Humanization of Pets: Treating Pets like Family

One of the prominent trends in the animal care market is the increasing humanization of pets. Pet owners are treating their animals more like family members, seeking products and services that cater to their pets' health, comfort, and emotional well-being. This trend has led to a growing demand for premium pet food, grooming services, and accessories designed to enhance the quality of life for companion animals.

Natural and Organic Products: A Shift towards Healthier Options

Consumers are becoming more conscious about the ingredients and materials used in pet care products, leading to a surge in demand for natural and organic alternatives. Pet owners are seeking products free from artificial additives, preservatives, and chemicals, opting instead for wholesome and sustainable options that promote the health and vitality of their pets. This trend has propelled the growth of natural pet food, eco-friendly toys, and biodegradable pet accessories in the market.

Telemedicine and Remote Veterinary Care: Convenient Healthcare Solutions

Advancements in technology have revolutionized the way veterinary care is delivered, with the adoption of telemedicine and remote monitoring solutions gaining traction in the animal care industry. Pet owners are increasingly turning to virtual consultations, telehealth platforms, and mobile apps to seek medical advice, diagnosis, and treatment for their pets, especially amid the COVID-19 pandemic. This trend has expanded access to veterinary services, improved convenience for pet owners, and facilitated early detection and intervention for pet health issues.

Personalized Nutrition and Wellness: Tailoring Care for Individual Pets

Pet owners are embracing personalized approaches to pet nutrition and wellness, recognizing that each animal has unique dietary and health needs. The demand for customized pet food formulations, tailored supplementation, and genetic testing services is on the rise as pet owners seek to optimize their pets' health and longevity. This trend has spurred innovation in the development of personalized pet nutrition plans, DNA testing kits, and health monitoring tools that cater to individual pets' requirements.

Sustainable and Ethical Practices

Environmental sustainability and ethical sourcing have become key considerations for pet owners when choosing products and services for their animals. There is a growing emphasis on eco-friendly packaging, cruelty-free ingredients, and ethical manufacturing practices in the animal care market. Companies are increasingly adopting sustainable initiatives, such as carbon-neutral operations, recyclable packaging, and ethical sourcing of raw materials, to align with consumer values and reduce their environmental impact.

Conclusion

The animal care market is evolving rapidly, driven by shifting consumer preferences, technological innovations, and societal trends. By staying attuned to these emerging trends and embracing innovation, companies can capitalize on new opportunities, differentiate their offerings, and meet the evolving needs of pet owners and their beloved companions. As the bond between humans and animals continues to strengthen, the animal care industry is poised for continued growth and transformation in the years to come.